Rahul Singhvi, Resilience CEO

Q&A: Re­silience boss Rahul Singhvi talks $2B US bio­man­u­fac­tur­ing ini­tia­tive and post Se­ries D deals

When the Biden ad­min­is­tra­tion an­nounced last week, through an ex­ec­u­tive or­der, that it is in­vest­ing $2 bil­lion in­to do­mes­tic ef­forts to in­crease biotech­nol­o­gy and bio­man­u­fac­tur­ing ef­forts, a lot of ears perked up in the wider man­u­fac­tur­ing world. Fund­ing is go­ing to­wards man­u­fac­tur­ing in­fra­struc­ture, train­ing, R&D and se­cu­ri­ty mea­sures, among oth­ers, some­thing that do­mes­tic man­u­fac­tur­ers are bull­ish about.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.